Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 17.2% – What’s Next?

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) were down 17.2% on Monday . The stock traded as low as $0.8885 and last traded at $0.9192. Approximately 239,728 shares changed hands during trading, an increase of 241% from the average daily volume of 70,238 shares. The stock had previously closed at $1.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Telomir Pharmaceuticals Stock Down 1.9%

The company’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.28. The company has a market cap of $72.90 million, a price-to-earnings ratio of -3.66 and a beta of -0.25.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its earnings results on Thursday, May 14th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $33,000. Raymond James Financial Inc. lifted its position in shares of Telomir Pharmaceuticals by 4,101.9% during the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after buying an additional 73,547 shares during the last quarter. Geode Capital Management LLC grew its position in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after acquiring an additional 27,519 shares during the last quarter. Marshall Wace LLP acquired a new position in Telomir Pharmaceuticals during the second quarter worth about $95,000. Finally, Jane Street Group LLC bought a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $62,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.